Ascendis Pharma A/S

6 de ago. de 2026, 20:06 UTC

Ascendis Pharma is trading higher after reporting significant findings from its Week 78 COACH trial, showing tripled height Z-score efficacy in children with achondroplasia.

4 de ago. de 2026, 19:36 UTC

Ascendis Pharma A/S is trading higher today, supported by positive market momentum despite recent negative economic data on U.S. core factory orders.

31 de jul. de 2026, 19:46 UTC

Ascendis Pharma A/S shares are lower today, trading significantly below their 20-day moving average amid broader market pressures from rising yields and inflation concerns.

30 de jul. de 2026, 19:09 UTC

Ascendis Pharma A/S shares are lower, continuing a decline since Wednesday. The stock is near the lower end of its one-month range.

28 de jul. de 2026, 20:01 UTC

Ascendis Pharma A/S shares are higher as the Biotechnology sub-sector advances. No specific company news was identified to explain today's price movement.

24 de jul. de 2026, 17:46 UTC

Morgan Stanley raised its price target for Ascendis Pharma to $275, maintaining an Overweight rating as shares trade higher during Friday's session.

22 de jul. de 2026, 18:36 UTC

Ascendis Pharma A/S shares are lower amid broader market sentiment affected by rising crude oil prices. The stock remains below its 20-day moving average.

21 de jul. de 2026, 20:12 UTC

Ascendis Pharma A/S shares are higher in after-market trading, supported by positive sentiment from strong earnings reports from companies like 3M and General Motors.

20 de jul. de 2026, 20:01 UTC

Ascendis Pharma A/S shares are lower today, continuing a decline from Friday's close amid notable volatility and no specific news to explain the movement.